Pdb37 Cost Effectiveness of Sodium-Glucose Cotransporter-2 (Sglt2) Inhibitors, Glucagon-Like Peptide 1 (Glp-1) Receptor Agonists, Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors: A Systematic Review

Abstract

and 166.2-337.0 in the severely obese subgroup alone. Conclusions: Further to the wide-ranging health benefits of maintaining normal body weight, even modest improvements in BMI could significantly reduce the financial burden of obesity in the US. Effective strategies to treat obesity may be best aimed at more overweight individuals for whom greatest changes in medical costs may be achieved.